MedTrace Logo

MRI-Driven Precision Typing and Response Prediction in Luminal Breast Cancer

NCT07692230 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2026-07-21

No results posted yet for this study

Summary

Luminal breast cancer is characterized by marked heterogeneity, resulting in diverse treatment responses and long-term outcomes. This project aims to integrate MRI and multiomics data to achieve non-invasive molecular typing and precise response prediction. By linking imaging phenotypes with underlying molecular and pathological characteristics, the investigators will develop predictive models for treatment resistance, recurrence, and metastasis, ultimately supporting personalized treatment strategies and precision oncology.

Conditions

  • HR Positive/HER-2 Negative Breast Cancer

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-06
Primary Completion
2027-12-31
Completion
2029-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07692230 on ClinicalTrials.gov